1303587-90-7 Usage
Chemical compound
2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)isonicotinic acid is a chemical compound.
Pharmaceutical applications
It has potential pharmaceutical applications.
Derivative of isonicotinic acid
It is a derivative of isonicotinic acid, which is a precursor in the synthesis of various pharmaceuticals.
Contains a dioxolane ring structure
It contains a dioxolane ring structure, which can impart biological activity to the molecule.
Potential as a prodrug
It may have potential as a prodrug, a compound that is metabolized in the body to release the active drug, due to the presence of the dioxolane group.
Utility in the development of new drugs
Further research into the pharmacological properties and potential therapeutic uses of 2-((2,2-dimethyl-1,3-dioxolan-4-yl)methoxy)isonicotinic acid may reveal its utility in the development of new drugs for various medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1303587-90-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,0,3,5,8 and 7 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1303587-90:
(9*1)+(8*3)+(7*0)+(6*3)+(5*5)+(4*8)+(3*7)+(2*9)+(1*0)=147
147 % 10 = 7
So 1303587-90-7 is a valid CAS Registry Number.
1303587-90-7Relevant academic research and scientific papers
BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS
-
Page/Page column 82-83, (2011/06/16)
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
